ReviewCancers2021
Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 23 citations in OpenAlex.
- Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells.Signal transduction and targeted therapy · 2026Article
- CT radiomics for survival risk stratification in resectable colorectal liver metastases: a multi-centre study.Scientific reports · 2026Article
- Therapeutic Strategies Targeting the Tumor-Stromal Microenvironment in Colorectal Cancer: A Narrative Review.Targeted oncology · 2026Review
- Review
- Tumor-Infiltrating Immune Cells Are More Abundant in Lung Metastases From Colorectal Cancer Than in Paired Primary Tumors and Their Prognostic Value Depends on Adjuvant Chemotherapy.Cancer medicine · 2026Article
- STAT6 inhibition of M2 macrophages suppresses tumor growth by modulating the tumor microenvironment in colon cancer model.Frontiers in immunology · 2026Article
- Organ-specific pre-metastatic and metastatic niches in colorectal cancer: "discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis".Frontiers in immunology · 2026Review
- Multimodal therapy and precision-imaging extends the limits of treatment for a patient with initially unresectable synchronous colorectal liver metastases.Annals of the Royal College of Surgeons of England · 2025Article
- Correlation between neutrophil-to-lymphocyte ratio, red blood cell distribution width, platelet distribution width, and colorectal adenoma: A retrospective cohort study.The Journal of international medical research · 2025Article
- The single-cell spatial landscape of stage III colorectal cancers.NPJ precision oncology · 2025Article
- Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer.BMC cancer · 2025Article
- The role of fungi in the diagnosis of colorectal cancer.Mycology · 2024Review
- Exosomal non-coding RNAs: Blueprint in colorectal cancer metastasis and therapeutic targets.Non-coding RNA research · 2023Review
- Review
- Regulatory role of exosomes in colorectal cancer progression and potential as biomarkers.Cancer biology & medicine · 2023Review
- Clinical application and detection techniques of liquid biopsy in gastric cancer.Molecular cancer · 2023Review
- Less demand on stem cell marker-positive cancer cells may characterize metastasis of colon cancer.PloS one · 2023Article
- Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment.Frontiers in immunology · 2023Review
- Liquid Biopsies in Colorectal Liver Metastases: Towards the Era of Precision Oncologic Surgery.Cancers · 2022Review
- Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.Molecular cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Colorectal cancer (CRC) is one of the most common cancers in western countries. Its mortality rate varies greatly, depending on the stage of the disease. The main cause of CRC mortality is metastasis, which most commonly affects the liver. The role of tumor microenvironment in tumor initiation, progression and metastasis development has been widely studied. In this review we summarize the role of the tumor microenvironment in the liver pre-metastatic niche formation, paying attention to the distant cellular crosstalk mediated by exosomes. Moreover, and based on the prognostic and predictive capacity of alterations in the stromal compartment of tumors, we describe the role of tumor microenvironment cells and related liquid biopsy biomarkers in the delivery of precise medication for metastatic CRC. Finally, we evaluate the different clinical strategies to prevent and treat liver metastatic disease, based on the targeting of the tumor microenvironment. Specifically, targeting angiogenesis pathways and regulating immune response are two important research pipelines that are being widely developed and promise great benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.